Although an increased level of tissue inhibitor of metalloproteinases (TIMP-1) has been proposed as a laboratory biomarker in the diagnosis of TAK, it is poorly specific, often occurring also in psoriasis, liver fibrosis, and cancer [47]. This evidence concerns the gene TIMP1 and Hepatic fibrosis.